Eva Winnebeck, PhD: Temporal Dynamics of Sleep
The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA
The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well
Neurology News Network for the week of October 6, 2018.
Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes
The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.
Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity
Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.
Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA
The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.
Stephen Silberstein, MD: Challenges in the Migraine Space
Silberstein spoke about the high prevalence of individuals with migraine in the United States, adding that the major problem in the space today is the lack of resources.
Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea
Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
Eva Winnebeck, PhD: Movement Rhythms During Sleep
The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.
Krista Lanctot, PhD: Managing Patients with Agitation
Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.
Geert Mayer, MD: Safety, Efficacy of Solriamfetol for Excessive Sleepiness In Narcolepsy, OSA
Long-term maintenance of efficacy was demonstrated with solriamfetol for treatment of excessive sleepiness with narcolepsy or obstructive sleep apnea.
Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer
Neurology News Network for the week of September 28, 2018.
A Study of Thousands: Adolescent Cognition and Alzheimer Disease
Potential risk factors may identify those at risk for AD and similar disorders as early as adolescence.
Irina Pikuleva, PhD: Activating CYP46A1 with Efavirenz
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.
Geert Mayer, MD: Solriamfetol As Potential Therapy for Excessive Sleepiness in Narcolepsy, Obstructive Sleep Apnea
The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.
Paul Newhouse, MD: Attacking Different Targets in Alzheimer
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.
Daphne Chylinski: Arousals During Sleep Are Strongly Linked to Alzheimer Disease Pathophysiology
Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.
Howard Fillit, MD: The Importance of Biomarkers for Alzheimer Disease
Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.
Krista Lanctot, PhD: Addressing Alzheimer Disease Agitation
The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.
Irina Pikuleva, PhD: Using Efavirenz in Alzheimer Disease
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.
Stephen Silberstein, MD: Understanding the Mechanism of Migraine
Silberstein spoke about the new mechanism-based treatments that are revolutionary in changing the treatment landscape of migraine.
FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS
Neurology News Network for the week of September 22, 2018.
Eugenia Trushina, PhD: Communication and Learning Through Collaboration
For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.
Paul Newhouse, MD: Exploring VU319 in Alzheimer Disease
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
Howard Fillit, MD: Emphasizing Care in Alzheimer Disease
With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.
Ronald Crystal, MD: Introducing Genetics into Alzheimer Disease
Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?
Eugenia Trushina, PhD: Mitochondria as a Therapeutic Target for Alzheimer
The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.
Patricia Coyle, MD: Multiple Sclerosis Symptom Management
Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.
Howard Fillit, MD: Alzheimer Disease Drug Development Improvement
The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.
Ronald Crystal, MD: APOE2 Gene Therapy for Alzheimer Disease
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.
